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A B S T R A C T
Background: A non-synonymous single nucleotide polymorphism of the ATG16L1 gene, T300A, is a major
Crohn’s disease (CD) susceptibility allele, and is known to be associated with increased apoptosis induction
in the small intestinal crypt base in CD subjects and mouse models. We hypothesized that ATG16L1 T300A
genotype also correlates with increased tumor apoptosis and therefore could lead to superior clinical out-
come in cancer subjects.
Methods: T300A genotyping by Taqman assay was performed for gastric carcinoma subjects who underwent
resection from two academic medical centers. Transcriptomic analysis was performed by RNA-seq on forma-
lin-fixed paraffin-embedded cancerous tissue. Tumor apoptosis and autophagy were determined by cleaved
caspase-3 and p62 immunohistochemistry, respectively. The subjects' genotypes were correlated with demo-
graphics, various histopathologic features, transcriptome, and clinical outcome.
Findings: Of the 220 genotyped subjects, 163 (74%) subjects carried the T300A allele(s), including 55 (25%)
homozygous and 108 (49%) heterozygous subjects. The T300A/T300A subjects had superior overall survival
than the other groups. Their tumors were associated with increased CD-like lymphoid aggregates and
increased tumor apoptosis without concurrent increase in tumor mitosis or defective autophagy. Transcrip-
tomic analysis showed upregulation of WNT/b-catenin signaling and downregulation of PPAR, EGFR, and
inflammatory chemokine pathways in tumors of T300A/T300A subjects.
Interpretation: Gastric carcinoma of subjects with the T300A/T300A genotype is associated with repressed
EGFR and PPAR pathways, increased tumor apoptosis, and improved overall survival. Genotyping gastric can-
cer subjects may provide additional insight for clinical stratification.









Our knowledge of cancer genetics has centered on oncogenes and
tumor suppressor genes [1,2]. Recent studies have demonstrated that
single nucleotide polymorphisms (SNPs) are also associated with
susceptibility to sporadic cancers [35]. To date, genome-wide asso-
ciation studies (GWAS) have identified nearly a thousand predisposi-
tion variants significantly associated with over thirty malignancies
[512]. These alterations have provided insights into new pathways
for tumorigenesis and new targets for therapeutics [5]. Although
most variants demonstrate a modest increase in risk [5], the com-
bined effects of multiple SNPs are potentially useful in population-
based cancer risk stratification and prevention programs [13,14].
Likewise, GWAS studies have also identified SNPs associated with
response to chemotherapy [15], treatment-related toxicity [16], and
clinical outcomes in cancer patients [1719]. Therefore, identifying
SNPs and other genetic alterations that correlate with clinical
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outcome may provide novel insight into the pathobiology and man-
agement of cancer.
One area of which GWAS has provided insight into disease patho-
genesis which resulted in mechanistic discoveries is immune-associ-
ated disorders [20]. Common SNPs/variants that increase the
susceptibility for inflammatory bowel disease (IBD), asthma, rheuma-
toid arthritis, and systemic lupus erythematosus have been identified
[11,2025], and some have also been associated with increased can-
cer risk [26]. Lessons from these informative studies have fostered
functional validations of selected SNPs. Most importantly, since these
SNPs may exert effects in a wide spectrum of tissue and cell types
[27], exploration of the role of these SNPs in other diseases such as
malignancy may yield new hypotheses and/or insights into tumori-
genesis through gene-specific, tissue-specific, or environment-spe-
cific mechanisms that merit testing.
Notably, some of the SNPs identified in immune-related disorders
are also common in non-disease control subjects, suggesting that
evolutionarily these SNPs may have acquired important roles in
maintaining tissue homeostasis [2729]. One such example is the
ATG16L1 Thr300Ala (T300A) SNP, the most significant susceptibility
SNP in the development of Crohn’s disease (CD) [30]. While originally
described as a key execution member of the autophagy pathway [31],
ATG16L1 is also known to affect multiple cell death pathways, includ-
ing apoptosis [32] and necroptosis [33]. We and others have shown
that Atg16l1 T300A mice showed defects in secretory cell lineages in
the gut, resulting in altered immunity that affects pathogen clearance
[29,34,35]. Notably, CD subjects harboring ATG16L1 T300A have more
aggressive disease course after resection [32,36,37]. Interestingly,
ATG16L1 T300A also confers protection from Escherichia coli infection
[28], but promotes Helicobacter pylori infection [38]. Thus, it is likely
that the effect of ATG16L1 T300A is organ- and disease-specific.
We previously showed that CD subjects and mice with ATG16L1
T300A possessed increased apoptosis (through repression of the
PPAR-g pathway) in the small intestinal crypt base [32]. Given the
role of apoptosis as a major cell death pathway employed to target
cancers [39], we hypothesized that ATG16L1 T300A may also confer
increased tumor apoptosis, which could lead to improved survival in
cancer. Herein we show that in gastric cancer, the T300A genotype is
associated with unique histologic features, increased cancer
apoptosis without concomitant increase in cancer proliferation or
autophagy deficiency, and importantly, superior overall survival.
2. Methods
2.1. Gastric cancer cases
Gastric cancer cases resected between 2008 and 2012 were retro-
spectively collected by searching the surgical pathology archives of
the University of Pittsburgh Medical Center (UPMC). Also included
were gastric cancer cases resected between 1999 and 2013 from the
Barnes-Jewish Hospital/Washington University. These cases were
first described by Olsen et al. [40]. The University of Pittsburgh Medi-
cal Center and the Barnes-Jewish Hospital/Washington University are
both large academic medical centers well-known in the United
States. Cases from both institutions were collected in the aforemen-
tioned time frame to ensure the post-surgical follow-up period is
long enough (at least 5 years) for survival analysis. For each subject /
case from the UPMC, the electronic medical records were reviewed
and the following demographic, clinical, and pathologic information
were retrieved: gender, race, age at operation, pathologic and clinical
stage, lymphovascular invasion, perineural invasion, status of surgical
resection margins, pre- and post-surgery treatments if received, his-
tory of Helicobacter pylori infection, and survival. For cases from the
Barnes-Jewish Hospital, the aforementioned demographic, clinical,
and pathologic information were updated and only cases with up-to-
date clinical follow-up information at the time of data collection
were included in this study.
2.2. Ethics statement
This study was approved by the Institutional Review Boards of the
University of Pittsburgh (STUDY20050115) and the Washington Uni-
versity (201301164). Informed consent from all participants was
waived by the IRB committees.
2.3. Histologic evaluation
Tissue sections of the carcinoma for each case were reviewed
without knowledge of the T300A genotype of each subject. Histologic
subtyping for each tumor was performed using criteria of the Lauren
classification system [41]. Specifically, a tumor is classified as intesti-
nal-type if the carcinoma demonstrates intestinal differentiation
with glandular / tubular structure formation. A tumor is classified as
diffuse-type if the carcinoma cells demonstrate lack of cohesiveness
(in other words lack of adhesion with each other) and infiltrating the
gastric wall as single cells or small clusters of tumor cells. A tumor is
classified as mixed-type if histologic features of both intestinal-type
and diffuse-type carcinomas are observed in the same tumor.
Histologic grading of each case was performed according to crite-
ria in the eighth edition of the American Joint Committee on Cancer
recommendation on cancer staging [42]. This histologic grading sys-
tem is based on the extent of glandular differentiation. In particular,
a well-differentiated adenocarcinoma (G1) is defined as a tumor with
greater than 95% of the tumor composed of glands. A moderately-dif-
ferentiated adenocarcinoma (G2) is a tumor with 50% to 95% of the
tumor composed of glands. A poorly-differentiated adenocarcinoma
(G3) is a tumor with 49% or less of the tumor composed of glands. In
this study, a tumor with mixed differentiation such as a mixed adeno-
neuroendocrine carcinoma was classified as histologic grade X (Gx).
The presence of a CD-like lymphoid reaction was evaluated as fol-
lows. For each case, all tumor sections were evaluated at lowmagnifi-
cation to find one section with the most intra- and peri-tumoral
lymphoid aggregates. In this tumor section, the number of intra- and
peri-tumoral lymphoid aggregates were counted in 3 consecutive
microscopic fields using 10£ objective lens and 10£ eye piece (the
Research in context
Evidence before this study
Single nucleotide polymorphisms can be associated with cancer
susceptibility and/or prognosis. We previously showed that the
ATG16L1 T300A variant, a major Crohn’s disease susceptibility
allele, induces apoptosis (through repression of the PPAR-g
pathway) in the small intestinal crypt base in CD subjects. Nota-
bly, CD subjects with the T300A/T300A genotype have more
aggressive disease course after surgical resection, whereas
T300A/T300A subjects with colorectal carcinoma demonstrate
superior prognosis.
Added value of this study
Our results demonstrate that the T300A/T300A genotype is
associated with superior overall survival, increased tumor apo-
ptosis and repressed EGFR and PPAR pathways in gastric
cancer.
Implications of all the available evidence
Genotyping of genes and variants that are not involved in onco-
genic or tumor suppressor pathways may provide insight in
stratifying gastric cancer subjects.
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use of both in combination yields a 100£ field of examination, which
corresponds to a surface area of 3 ¢8 mm2 using an Olympus BX46
microscope). When on average the number of lymphoid aggregates
was one or more (mean number of lymphoid aggregates per
100 £ field  1), the tumor was scored as positive for CD-like lym-
phoid reaction.
Mitotic activity of each tumor was evaluated by counting the
number of mitotic figures in the most mitotically active area in the
tumor. Briefly, for each case, all tumor sections were first evaluated
at low magnification to find a “hotspot” area with the most mitotic
activity. In the “hotspot” area, the number of mitotic figures was then
counted in 3 consecutive high-power fields (one high-power
field = 400 £ [40 £ objective lens and 10£ eye piece], which corre-
spond to a surface area of 0 ¢24 mm2 using an Olympus BX46 micro-
scope). The mean number of mitotic figures in one high-power field
(400£) was calculated for each tumor.
2.4. Genotyping
Genomic DNA was extracted from formalin-fixed paraffin-embed-
ded (FFPE) tissue using the QIAamp DNA FFPE tissue kit (Qiagen Inc.,
Valencia, CA, catalog number: 56404) and subsequently used for
T300A genotyping with TaqMan SNP Genotyping Assay (Thermo
Fisher Scientific, catalog number: 4351379) following the manufac-
turer’s instructions.
2.5. Immunohistochemistry and in-situ hybridization
For cleaved caspase-3 immunohistochemistry, unstained slides
were deparaffinized, followed by antigen retrieval using Trilogy (Cell
Marque, catalog number: 920P-09). The slides were quenched with
10% H2O2 in methanol for 10 min, before being blocked with 1%
bovine serum albumin and 0.1% Trizol in phosphate buffer saline for
1 h. Thereafter, primary antibody (1:200; Cell Signaling, RRID:
AB_2069869) was applied overnight. After overnight incubation, goat
anti-rabbit biotinylated secondary antibody (1:200; ThermoFisher
Scientific, catalog number: 31820) was applied for 45 min. Signal
detection was then performed by using Vectastain Elite ABC kit (Vec-
tor, catalog number: PK-6100) and DAB (Vector, RRID: AB_2336520).
Immunohistochemistry stains with CD4 (clone SP35, Ventana, cat-
alog number: 790-4423), CD8 (clone CD8/144B, DAKO, catalog num-
ber: M7103), CD56 (clone 123C3.D5, Ventana, RRID: AB_2335987),
EGFR (clone 3C6, Ventana, RRID: AB_2335974), c-MYC (clone Y69,
Ventana, catalog number: 790-4628), p62 (clone 3/P62 LCK ligand,
BD Biosciences, RRID:AB_398151), MLH1 (clone M1, Ventana, catalog
number: 790-4535), MSH2 (clone G219-1129, Ventana, catalog num-
ber: 760-4265), MSH6 (clone 44, Ventana, catalog number: 790-
4455), and PMS2 (clone EPR3947, Cell Marque, catalog number:
288M-18) antibodies were performed on unstained 4 mm tissue sec-
tions using the Ventana XT automated stainer (Ventana Medical Sys-
tems) according to the manufacturer’s recommendations. All cases
were tested for Epstein  Barr virus (EBV) by in-situ hybridization
using pre-diluted probes targeting EBV encoded early RNA (EBER,
Ventana, catalog number: 760-1209) using the Ventana XT auto-
mated stainer. All cases tested for EBER were also tested for the integ-
rity of total RNA using RNA control probe (Leica, catalog number:
RS7760) and all showed adequate total RNA preservation.
2.6. Quantitative digital image analysis of CD8-positive or CD4-positive
T cell density and CD56-positive NK cell density
The CD4, CD8, and CD56 stained slides were digitized using an
Aperio AT2 scanner (Leica Biosystems, Buffalo Grove, IL) at 40x mag-
nification. The CD4 immunostained slide and CD8 stained slide for
each case were manually annotated to outline the areas of invasive
adenocarcinoma. Non-neoplastic gastric tissue and areas of necrosis
were specifically excluded from the area of analysis. The Aperio
nuclear v9 algorithm, a component of the commercially available
Leica/Aperio image analysis platform, was used to count the CD4- or
CD8-stained cells as previously described [43]. The CD4-positive or
CD8-positive T cell density was determined by dividing the number
of CD4-positive or CD8-positive cells by the area (measured in mm2)
examined. Densities (number of cells / mm2) of CD56-positive, CD4-
positive, or CD8-positive cells in peri- and intratumoral lymphoid
aggregates were additionally determined using the same algorithm.
2.7. Transcriptomic analysis
For each tumor included in transcriptomic analysis, a representa-
tive FFPE tumor tissue block was selected. The tumor area desired for
transcriptomic analysis was manually circled on the hematoxylin and
eosin stained tissue section. Manual microdissection of the desired
tumor area was then performed on 6 to 10 unstained tumor tissue sec-
tions at 10 mm thickness for each tumor to ensure that only area of
viable tumor but not necrosis or uninvolved tissue was included in
transcriptomic analysis (Supplementary Fig. 1). Total RNA was
extracted frommanually dissected tumor tissue using the Qiagen miR-
Neasy mini kit (Qiagen Inc., catalog number: 74104) according to the
manufacturer’s recommendations. RNA library was prepared using the
TruSeq RNA ACCESS library preparation kit (Illumina, San Diego, CA,
catalog number: 15049525). Transcriptomic analysis was performed
on the NextSeq 500 system according to the manufacturer’s recom-
mendations (please see Supplementary Method for details).
Quality of the RNAseq results of all 47 cases were assessed using
FastQC (v0.11.5). All 47 cases fulfilled the quality control parameters.
Samples were then aligned to the GRCh38 genome with HISAT2
(v2.1.0) [44] and to the human transcriptome with Salmon (0.11.0)
[45]. Alignments were quality assessed with QoRTs (v1.1.8) [46] and
RNASeQC (v1.1.8) [47]. Gene expression was quantified with HTSeq
(v0.9.0) [48]. Data normalization with the weighted trimmed mean
ofM-values (TMM) method and differential gene expression between
T300A genotypes were performed with the edgeR R package [49].
BenjaminiHochberg method was used for correction of multiple
testing for differential gene expression.
Differentially expressed genes with P < 0 ¢01 were further ana-
lyzed by a novel knowledge engine called ‘COmprehensive Multi-
omics Platform for Biological InterpretatiOn’ (CompBio: https://
www.percayai.com/CompBio) [50]. CompBio performs a literature
analysis to identify relevant biological processes and pathways repre-
sented by the differentially expressed entities (genes, proteins, miR-
NA’s, or metabolites). This is accomplished with an automated
Biological Knowledge Generation Engine that extracts all abstracts
from PubMed that reference entities of interest (or their synonyms),
using contextual language processing and a biological language dic-
tionary that is not restricted to fixed pathway and ontology knowl-
edge bases. Conditional probability analysis calculates the statistical
enrichment of biological concepts (processes/pathways) over those
that occur by random sampling. Related concepts built from the list
of differentially expressed entities are further clustered into higher-
level themes (e.g., biological pathways/processes, cell types and
structures, etc.). The dataset was then cross-referenced with the
T300A/T300A-specific transcriptomic themes identified in mouse
ileum (ArrayExpress database E-MTAB-5707) [32].
2.8. Statistics
Statistical analysis was performed with GraphPad Prism 7 for
Windows Version 7.00 (GraphPad Software, La Jolla, CA) and IBM
SPSS (Release 23.0.0.0). GraphPad Prism 7 was used to perform both
paired and unpaired Student t-tests, MannWhitney test, and Krus-
kalWallis test, which were used for comparison of continuous varia-
bles. IBM SPSS was used to perform survival analysis, Two-sided
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Fisher’s exact test, and Chi-Square test. The latter two tests were used
for the comparison of categorical data. HardyWeinberg equilibrium
testing was performed by comparing observed genotype frequencies
with those expected in Caucasian subjects and in African American
subjects by Chi-Square test in R using the package named Har-
dyWeinberg (https://cran.r-project.org/web/packages/HardyWein
berg/HardyWeinberg.pdf). All tests were two-tailed and a P value less
than 0 ¢05 (P < 0 ¢05) was considered significant. For survival analy-
sis, overall survival was defined as the duration between surgical
resection and either death or the latest clinical follow-up time. Death
occurring within one month of the initial operation was attributed to
operative mortality and was not included in the survival analysis. Sub-
jects who were clinical stage IV at the time of surgery, i.e., with distant
metastasis at the time of surgery, were considered never disease free
and hence excluded from the analysis for disease-free survival. Sur-
vival analysis was performed using Cox proportional hazard model
and Kaplan-Meier analysis with log-rank statistics. Potential con-
founding factors in univariate and/or multivariate analysis included
race, histologic grade, histologic subtype by Lauren classification, clini-
cal stage, surgical resection margin, lymphovascular invasion, perineu-
ral invasion, Helicobacter pylori infection, and chemotherapy.
Sequencing files are deposited at Gene Expression Omnibus (GEO)
under accession number GSE152415.
2.9. Role of funding source
The funder (NIH) did not have any role in study design, data col-
lection, data analyses, interpretation, or writing of report.
3. Results
3.1. Characteristics of the gastric cancer cohort
We retrospectively collected tissue from 220 consecutively
resected gastric cancer subjects from two academic medical centers
for genotyping and histopathology analysis. Among them, 163 (74%)
subjects carried the T300A allele(s), including 55 (25%) homozygous
T300A/T300A and 108 (49%) heterozygous T300A/wild-type (WT)
subjects. Homozygous WT/WT genotype was detected in 57 (26%)
subjects. The flow diagram of the gastric cancer cases analyzed in this
study is shown in Fig. 1, and the demographics and clinicopathologic
characteristics of the 220 genotyped subjects are listed in Table 1.
The T300A allele frequency was 0 ¢56 and the WT allele frequency
was 0 ¢44 in Caucasian subjects in our cohort. In African American
subjects the allele frequency was 0 ¢23 for the T300A allele and 0 ¢77
for the WT allele. Allele frequencies of the T300A SNP in our cohorts
were comparable to those reported in public databases [30]. In addi-
tion, genotype frequencies in Caucasian subjects and African Ameri-
can subjects did not deviate from HardyWeinberg equilibrium
(P > 0 ¢05 [Chi-Square test]). Since the T300A allele is more frequent
in Caucasians than in African American subjects, homozygous T300A/
T300A genotype was more frequently identified in Caucasians than
other genotypes (P < 0 ¢01 [Fisher’s exact test]; Table 1). Only 33
(15%) subjects had either clinical history or active/concurrent Helico-
bacter pylori infection. When stratified by genotype, Helicobacter
pylori infection was more often seen in homozygous WT/WT subjects
than in subjects with other genotypes (14/57, 25% versus 11/108, 10%
versus 8/55, 15%). However, this difference was not statistically sig-
nificant (P = 0 ¢07 [Fisher’s exact test]; Table 1). There was also no
significant difference in the histologic degree of tumor differentia-
tion, histologic type by the Lauren classification [41], clinical stage,
receipt of pre- and post- surgical treatment, or other histopathologic
parameters between different genotype groups (P > 0 ¢05 for all
[Fisher’s exact test]; Table 1).
3.2. Gastric cancer subjects with ATG16L1 T300A/T300A showed
superior prognosis after surgery
We next assessed if the ATG16L1 T300A genotype correlated with
clinical outcome. Among all 220 subjects with confirmed genotypes,
those with the T300A/T300A genotype showed superior overall sur-
vival compared to the other two groups combined (WT/T300A and
WT/WT) by Kaplan-Meier survival analysis with log-rank statistics
(mean, standard error, and 95% confidence interval [CI] of overall sur-
vival: 107 months, 14 months, [80135] versus 64 months, 9
months, [5276], P = 0 ¢035) (Fig. 2a). Using Cox proportional haz-
ards modeling, however, the T300A/T300A genotype was not an
independent predictor of overall survival for the entire cohort in mul-
tivariate analysis (multivariate analysis hazard ratio and 95% CI:
0 ¢77, 0 ¢47  1 ¢26, P = 0 ¢31) (Supplementary Table 1).
In order to exclude potential confounding effects on overall sur-
vival introduced by pre- and post-surgical chemotherapy, we next
performed survival analysis in the subset of 126 subjects who
received only surgical treatment. Among them, subjects with T300A/
T300A genotype had significantly longer overall survival than sub-
jects with WT/T300A andWT/WT genotypes combined using Kaplan-
Meier survival analysis with log-rank statistics (mean, standard
error, and 95% CI: 164 months, 16 months, [132196] versus 60
months, 5 months, [5169], P = 0 ¢019) (Fig. 2b). Using Cox propor-
tional hazards modeling, the T300A/T300A genotype was associated
with a significant increase in overall survival by both univariate and
multivariate analysis (multivariate analysis hazard ratio and 95% CI:
0 ¢31, 0 ¢110 ¢88, P = 0 ¢03) (Table 2).
Approximately one-third (45, 36%) of the 126 subjects with surgery
as the only treatment died during the follow-up period. WT/WT sub-
jects had significantly higher mortality than subjects with other T300A
genotypes (WT/WT: 19/35, 54% versus WT/T300A: 20/57, 35% versus
T300A/T300A: 6/30, 20%, P = 0 ¢02 [Fisher’s exact test]). The percen-
tages of patients who died of disease progression were similar
between the three groups: 7/19 (37%) in WT/WT, 7/20 (35%) in WT/
T300A, and 2/6 (33%) in T300A/T300A groups (P = 0 ¢73 [Fisher’s exact
test]). Likewise, other comorbidities and surgical complications
accounted for death in 12/19 (63%) WT/WT, 13/20 (65%) in WT/T300A,
and 4/6 (67%) in T300A/T300A groups (Supplementary Table 2).
3.3. T300A/T300A genotype was associated with unique histological
features
We and others have previously found that T300A/T300A genotype
was associated with histomorphologic changes in CD subjects and
mouse models [34,51,52], including increased apoptosis induction in
Fig. 1. Flow chart illustrating type of analysis and number of cases. Flow diagram of the
number of subjects genotyped and the number of cases analyzed for histopathologic
features, clinical outcome, and transcriptomes.
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small intestinal crypt base where Paneth cells and intestinal stem
cells (both are CD-relevant cell types) reside [53]. We therefore
hypothesized that T300A/T300A genotype was also associated with
unique histologic features in gastric cancer. To exclude the possibility
that neoadjuvant therapy may affect histologic features, we per-
formed histologic assessments of the tumors from subjects who did
not receive neoadjuvant therapies, including subjects who received
no additional treatment either before or after surgery and those who
received only adjuvant treatment. Cases with tumor blocks available
(n = 119) were included in histologic evaluation (Fig. 1). As shown in
Supplementary Table 3, there was no significant difference in Helico-
bacter pylori infection, the histologic degree of tumor differentiation,
histologic subtype, clinical stage, or other histologic features between
different genotype groups (P > 0 ¢05 for all [Fisher’s exact test]).
In contrast, we found that the T300A/T300A tumors were more
likely to contain intra- and peri-tumoral CD-like lymphoid aggregates
than homozygous WT/WT tumors (25/28, 89% versus 21/32, 66%,
P = 0 ¢037 [Fisher’s exact test]) (Fig. 3a, b, and Table 3). We further
analyzed the density of lymphocytes not associated with lymphoid
aggregates, using an unbiased automated image analysis system [43].
There was no difference in the density of CD8-positive or CD4-posi-
tive T cells at the tumor invasive front (tumor-stroma interface)
(P = 0 ¢60 and 0 ¢89, respectively, [Kruskal-Wallis test]) or within
the tumors (P = 0 ¢72 and 0 ¢61, respectively, [Kruskal-Wallis test])
(Supplementary Table 4 and Supplementary Fig. 2). We additionally
analyzed the density of CD4-positive T cells, CD8-positive T cells, and
CD56-positive NK cells in peri- and intratumoral lymphoid aggre-
gates using the same automatic image analysis system [43]. These
lymphoid aggregates contained similar proportions of CD4-positive T
cells and CD8-positive T cells (mean and standard deviation: CD4-
positive T cell density: 1587 § 618 versus CD8-positive T cell density:
1556 § 611; P = 0 ¢78 [paired t-test]). The ratio of CD4-positive cell
density and CD8-positive cell density was not associated with tumor
T300A genotypes (mean and standard deviation of CD4 cell density /
CD8 cell density: WT/WT: 1 ¢06 § 0 ¢38 versus T300A/T300A:
1 ¢11 § 0 ¢76; P = 0 ¢63 [Mann-Whitney test]) (Supplementray
Figs. 3a, c, and d). In contrast CD56-positive NK cell was not a signifi-
cant component in peri- and intratumoral lymphoid aggregates (Sup-
plementray Figs. 3b and e).
3.4. T300A/T300A genotype was associated with increased tumor
apoptosis
Given the role of ATG16L1 T300A in mediating various cell death
pathways, predominantly autophagy and apoptosis, we next deter-
mined if proliferation, autophagy, and apoptosis were differentially
correlated with subject genotypes. We found that there was no dif-
ference in the mitotic activities in the tumors of the T300A/T300A
group compared to the others (P = 0 ¢64 [Kruskal-Wallis test]) (Sup-
plementary Figs. 4a, b, and Supplementary Table 4). Likewise, as a
Table 1
Demographics and clinicopathologic characteristics stratified by T300A genotype.
All cases(N = 220) WT/WT(N = 57) WT/T300A(N = 108) T300A/T300A(N = 55) P
Age (year; median, [IQR]) 73 (19) 75 (15) 71 (20) 72 (22) 0.40
Gender (n, %)
Female 96 (44) 28 (49) 48 (44) 20 (36) 0.38
Male 124 (56) 29 (51) 60 (56) 35 (64)
Race (n, %) N = 167 N = 41 N = 82 N = 44
Caucasian 135 (81) 24 (59) 71 (87) 40 (91) < 0.01
African American 20 (12) 13 (32) 5 (6) 2 (5)
Others 12 (7) 4 (10) 6 (7) 2 (5)
Histologic type (n, %)
Intestinal 104 (47) 31 (54) 45 (42) 28 (51) 0.48
Diffuse 84 (40) 18 (32) 49 (45) 20 (36)
Mixed and other types 29 (13) 8 (14) 14 (13) 7 (13)
Histologic grade (n, %)
G1 14 (6) 2 (4) 7 (6) 5 (9) 0.14
G2 57 (26) 21 (37) 20 (19) 16 (29)
G3 146 (66) 33 (58) 79 (73) 34 (62)
Gx 3 (1) 1 (2) 2 (2) 0
Clinical stage (n, %)
I 72 (33) 17 (30) 31 (29) 24 (44) 0.10
II 58 (26) 20 (35) 25 (23) 13 (24)
III 62 (28) 16 (28) 32 (30) 14 (25)
IV 26 (12) 3 (5) 19 (18) 4 (7)
Unknown 2 (1) 1 (2) 1 (1) 0
Positive resection margin (n, %) 34 (15) 8 (14) 20 (19) 6 (11) 0.44
Positive lymphovascular invasion (n, %) 135 (61) 33 (58) 71 (66) 31 (56) 0.31
Positive perineural invasion (n, %) 93 (42) 21 (37) 52 (48) 20 (36) 0.29
Helicobacter pylori infection (n, %) 33 (15) 14 (25) 11 (10) 8 (15) 0.07
Vital status (at the time of data collection) (n, %)
Alive 93 (43) 21 (37) 43 (40) 29 (53) 0.24
Death 121 (55) 34 (60) 61 (56) 26 (47)
Lost to follow-up 6 (3) 2 (4) 4 (4) 0
Overall follow-up time (month; median, [IQR]) 25 (46) 21 (51) 20 (41) 37 (53) 0.02
Recurrence (at the time of data collection) (n, %) N = 178 N = 49 N = 81 N = 48
No 116 (65) 30 (61) 56 (69) 31 (65) 0.73
Yes 62 (35) 19 (39) 26 (32) 17 (35)
Disease free time (month; median, [IQR]) 23 (46) 18 (45) 22 (48) 25 (44) 0.37
Chemotherapy (n, %)
None 126 (57) 36 (63) 60 (56) 30 (55) 0.79
Neoadjuvant only 13 (6) 2 (4) 7 (6) 4 (7)
Adjuvant only 46 (21) 13 (23) 23 (21) 10 (18)
Both 35 (16) 6 (11) 18 (17) 11 (20)
Abbreviations: WT: wild-type; IQR: interquartile range; G: grade.
Kruskal-Wallis test was used for comparison of continuous variables. Fisher’s Exact Test was used for the comparison of categorical data.
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readout for autophagy activation, the prevalence of p62-positive
immunohistochemical staining was similar between all groups
(P = 0 ¢27 [Chi-Square test]) (Supplementary Figs 4c, d, and Supple-
mentary Table 4). In contrast, the T300A/T300A tumors showed sig-
nificantly increased intratumoral apoptosis compared with tumors of
other genotypes (P = 0 ¢04 [Kruskal-Wallis test]) by cleaved-caspase
3 immunohistochemistry (Figs. 3c, d, e, f, and Table 3). Therefore, the
T300A/T300A genotype was associated with increased intratumoral
apoptosis without concurrent changes in autophagy activation or
mitosis.
3.5. Gastric cancer from T300A/T300A subjects showed unique
transcriptomic signatures
To further characterize the pathways that may be involved in
mediating the apoptosis induction in the T300A/T300A tumors, we
performed global transcriptomics on a subset of 47 tumors that did
not receive neoadjuvant therapies (including 13 WT/WT,
17 WT/T300A, and 17 T300A/T300A cases) (Fig. 1). Of note, since gas-
tric carcinoma with DNA mismatch repair (MMR) protein deficiency
Fig. 2. Gastric cancer subjects with T300A/T300A genotype had superior overall survival. Kaplan-Meier survival analysis using log-rank statistics comparing the overall survival of
subjects with gastric carcinoma stratified by T300A genotype in the entire cohort (n = 220, P = 0 ¢ 035 [log-rank]) (a) and in the subset of subjects without additional pre- or post-sur-
gical treatment (n = 126, P = 0 ¢019 [log-rank]) (b).
Table 2
Univariate and multivariate analysis of overall survival in subjects without additional




Univariate analysis Multivariate analysis
P HR 95% CI P HR 95% CI
T300A/T300A 0.02 0.37 0.160.88 0.03 0.31 0.110.88







Stage III & IV < 0.001 6.0 2.9812.24 0.02 3.0 1.167.74
Positive surgical
resection margin
0.01 2.85 1.246.56 0.96 0.97 0.322.94
Lymphovascular
invasion
< 0.001 5.45 2.5711.57 < 0.001 4.11 1.869.07




Abbreviations: HR: hazard ratio; CI: confidence interval.
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Fig. 3. Tumors from T300A/T300A subjects showed more lymphoid aggregates and apoptosis. (a) T300A/T300A tumors were more likely to have intra- and peritumoral lymphoid aggre-
gates thanWT/WT tumors (P = 0 ¢037 [Fisher’s exact test]) (WT/WT n = 32, WT/T300A n = 55, T300A/T300A n = 28). (b) Representative photomicrograph of a gastric adenocarcinoma
with intra- and peritumoral lymphoid aggregates (arrows). (c) Representative photomicrograph of a WT/WT tumor with 6% of cleaved-caspase 3-positive (CC3+) tumor cells
(arrows) / 400£ field on average in 5 representative fields. (d) Representative photomicrograph of a WT/T300A tumor with 6% of CC3+ tumor cells (arrows) / 400£ field on average
in 5 representative fields. (e) Representative photomicrograph of a T300A/T300A tumor with 10% of CC3+ tumor cells (arrows) / 400£ field on average in 5 representative fields. (f)
T300A/T300A tumors had significantly increased CC3+ tumor cells compared with tumors of the other two genotypes (P = 0 ¢04 by ANOVA) (WT/WT n = 30, WT/T300A n = 30,
T300A/T300A n = 26). Error bars represent mean with 95% confidence interval. Scale bars: b-200 mm; c, d, e-50mm.
Table 3
Tumor immune microenviroment and apoptosis by cleaved-caspase3 immunoistochemistry stratified by T300A genotype.
WT/WT WT/T300A T300A/T300A P1 P2 P3
Peri- and intra-tumoral lymphoid aggregates (n, %) N = 32 N = 55 N = 28
Negative (< 1 / 100 £ field) 11 (34) 10 (18) 3 (11) 0.06 0.18 0.037
Positive ( 1 / 100 £ field) 21 (66) 45 (82) 25 (89)
No. of cases stained for CC3 N = 30 N = 30 N = 26
% of CC3-positive tumor cells / 400£ field (median, [IQR]) 4.7 (5.1) 5.2 (3.5) 6.8 (5.5) 0.04 0.01 0.04
Kruskal-Wallis test and Mann-Whitney test were used for comparison of continuous variables. Fisher’s exact test was used for the
comparison of categorical data.
Abbreviations: WT: wild-type; IQR: interquartile range; CC3: cleaved-caspase 3.
1 P-value for the comparison between all three groups.
2 P-value for the comparison between WT/WT and WT/T300A combined and T300A/T300A (WT/WT & WT/T300A vs. T300A/
T300A).
3 P-value for the comparison between WT/WT and T300A/T300A.
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/microsatellite instability (MSI) or Epstein - Barr virus (EBV) infection
have distinct molecular features [54], tumors that were MMR defi-
cient/MSI or EBV-positive were also excluded from transcriptomic
analysis. Manual microdissection was also performed to ensure that
only area of viable tumor and not necrosis or uninvolved tissue was
submitted for bulk transcriptomic analysis for each tumor to mini-
mize potential transcriptomic variations caused by differences in cell
types (Supplementary Fig. 1). Transcriptomic analysis yielded 487
significantly expressed genes associated with the T300A/T300A geno-
type, including 296 upregulated genes and 191 downregulated genes
(P < 0 ¢001) (Fig. 4a and Supplementary Table 5). These were used
subsequently in pathway analysis.
Using a novel biological knowledge generation engine (CompBio)
[50], we identified biological processes that were associated with
cancers from subjects with different genotypes. The T300A/T300A
tumors showed upregulation of genes involved in the following
themes: embryonic stem cell reprogramming, immunoglobulin,
WNT/b-catenin signaling, and microvessel density (Fig. 4b and Sup-
plementary Fig. 5). In addition, these tumors also showed repression
of expression of genes involved in the following transcriptomic
themes: PPAR pathway, EGFR signaling, and inflammatory chemo-
kines (CCL2, CXCL2, CCL13, CCL3l3, IL-6), among others (Fig. 4c and
Supplementary Fig. 6). Previous studies demonstrated that the T300A
mutation is associated with type I interferon (IFN) activation in colon
cancer cells in vitro [55] and in mouse model [29]. A type I IFN mRNA
expression signature was not detected in T300A/T300A tumors in our
cohort (Supplementary Fig. 7 and Supplementary Table 6).
Immunohistochemistry study of selected genes with up regulated
(c-MYC) and down regulated (EGFR) RNA expression in T300A/T300A
tumors demonstrated strong c-MYC staining but a lack of EGFR stain-
ing in T300A/T300A tumors (Supplementary Figs. 8 and 9). In con-
trast, WT/WT or WT/T300A tumors showed strong EGFR staining
without c-MYC staining. These findings support that gene expression
alterations observed from transcriptomic analysis are associated with
tumor T300A genotypes.
Finally, to understand how much the transcriptomic themes iden-
tified are generalizable between different tissue types, we also com-
pared the data to our previously published dataset where full-
thickness ileal tissue between T300A/T300A and WT/WT mice were
compared [32]. Using CompBio, we identified several common tran-
scriptomic themes between the two datasets. Most of the transcrip-
tomic themes identified as upregulated in the T300A/T300A gastric
cancers were also seen in the T300A/T300A mouse ileum (Supple-
mentary Fig. 10a) whereas themes associated with mesenchymal
stem cells, retinoic acid signaling, chemokines, and PPAR signaling
were common downregulated transcriptomic themes between the
T300A/T300A gastric cancers and T300A/T300A mouse ileum (Sup-
plementary Fig. 10b). Overlapping genes in association with the
T300A/T300A between the two datasets are shown in Supplementary
Tables 7 and 8. Therefore, despite the species and organ differences,
we identified common transcriptomic themes associated with the
T300A/T300A genotype.
4. Discussion
Recent advances in cancer genetics have focused on genes whose
functions are beyond the roles of oncogenes and tumor suppressor
genes. In particular, genetic studies from immune-associated diseases
have shown that common SNPs can be associated with disease-rele-
vant pathophysiologic changes. In the current study, we hypothe-
sized that a well-studied SNP associated with CD susceptibility,
ATG16L1 T300A, may be associated with survival difference in cancer
subjects. We showed that the T300A/T300A genotype was associated
with superior overall survival in gastric cancer subjects. Histologi-
cally, the T300A/T300A genotype was associated with CD-like lym-
phoid aggregates and prominent cancer cell apoptosis. Finally, the
molecular signatures associated with these tumors provided possible
mechanisms by which the T300A allele functions.
In contrast to its survival benefit in gastric cancer demonstrated in
our study, the T300A/T300A genotype is associated with more
aggressive clinical phenotype and disease course in CD [32,56]. The
dichotomy may be due to the biologic processes involved in different
disease contexts. In CD, increased crypt base apoptosis leads to Pan-
eth cell defect, resulting in diminished innate immunity and dysbio-
sis, whereas, in gastric cancer, increased tumor apoptosis without
concomitant increase in tumor proliferation leads to improved sur-
vival. This is supported by a recent study demonstrating the T300A
phenotype differences are stimulation (environmental factors)- and
cell type-dependent [57]. On the other hand, survival benefit of the
T300A/T300A genotype has also been shown in colorectal and non-
Fig. 4. Transcriptomic analysis identified gene signatures associated with T300A/T300A
genotype in gastric cancer. (a) Intensity plot of normalized gene expression level for
487 significantly expressed genes (P < 0 ¢ 01) associated with the T300A/T300A geno-
type (WT/WT & WT/T300A n = 30, T300A/T300A n = 17). (b) Transcriptomic themes
from genes upregulated in the T300A/T300A tumors performed by CompBio analysis.
(c) Themes from genes downregulated in the T300A/T300A tumors performed by
CompBio analysis.
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small cell lung cancers [55,58]. Our study suggests that the protective
effect of the T300A may be common to multiple cancer types,
although the mechanisms by which T300A confers improved survival
may be organ-specific. In particular, the T300A/T300A genotype was
not associated with a decrease in clinical stage IV/metastatic gastric
carcinoma in our cohort. More importantly, the main molecular path-
ways associated with T300A in gastric carcinoma may be different
from pathways identified in colon cancer. Type I IFN activation was
detected in human colon cancer cell line with T300A mutation [55]
but was not detected in gastric carcinoma with T300A/T300A geno-
type.
Notably, the ATG16L1 T300A variant has been associated with sus-
ceptibility of gastric cancer. In the study by Burada et al., the risk of
developing gastric carcinoma was significantly reduced (odds ratio:
0 ¢52, 95% confidence interval 0 ¢130 ¢88, P = 0 ¢013) in subjects car-
rying the T300A allele compared with those with WT/WT genotype in
a cohort of 350 Romanian subjects [59]. In contrast, the T300A allele
was associated with an increased risk of gastric carcinoma (adjusted
odds ratio: 2 ¢38, 95% confidence interval 1 ¢344 ¢24, P = 0 ¢003) in
304 ethnic Chinese subjects [60]. These findings suggest that the
ATG16L1 T300A allele may be associated with susceptibility of gastric
cancer but its impact may be population specific. Additionally, studies
performed in Crohn's disease have shown that the genetics underly-
ing disease prognosis may be independent of the genetics underlying
disease susceptibility [61]. Further validation of the association
between T300A genotype and gastric cancer susceptibility will ideally
require studying large numbers of subjects, as has been performed in
other disease types [35,30,6164]. However, our findings together
with results in colon and non-small cell lung cancers may imply a
survival benefit of the T300A allele against carcinoma. In addition, we
feel, this protective effect may be generalizable to wider populations
given the relatively large number of subjects from different geo-
graphic areas included in our study (St. Louis and Pittsburgh, U.S.)
and studies of colorectal carcinoma (n = 460, Chicago, U.S.) [55] and
non-small cell lung cancer (n = 323, China) [58].
A unique feature of our study is the focus on transcriptomics of
tumors that are not associated with known outcome confounders
such as MSI or EBV infection, as these are also known to have distinct
pathogenic pathways [54,65,66]. In addition, we have also focused
our analysis on subjects who did not receive pre-surgery treatment,
such that the histopathologic and transcriptomic readouts were not
affected by other therapeutic modalities.
Our transcriptomic study provides insight into the etiopatho-
genesis by which SNP variants of autophagy genes may modulate
tumor biology. Importantly, despite the difference in species and
organs, we were able to validate key transcriptomic themes in
the gastric cancer dataset specific to T300A/T300A genotype using
our previously published mouse model [32]. The correlation
between the T300A/T300A genotype and repressed PPAR signal-
ing is also in keeping with our previous study in CD patients and
mouse model which showed that hosts with T300A were prone
to have repressed PPAR-g signaling [32]. It further validates our
previous mouse model by which repressed PPAR signaling
directly links to increased apoptosis [32]. Our data is also consis-
tent with a previous study which showed that activated PPAR sig-
naling negatively correlated with prognosis in gastric cancer
patients, possibly through regulating lipid and fatty acid metabo-
lism [67]. Therefore, one possible mechanism by which T300A
confers survival benefit in gastric cancer is through repression of
PPAR pathway. As PPAR agonists are being developed for gastric
cancer patients [67,68], our study provides a unique insight into
the patient population that may benefit most from this therapy.
Potential limitations of our study include the retrospective study
design, and the lack of in vitro and/or in vivo studies to further define
the role of the identified molecular pathways. Prospective studies
with a larger cohort with more complete clinical data and in vitro/in
vivo studies for mechanisms are needed to validate the findings
described in our study.
In summary, we showed that CD susceptibility allele ATG16L1
T300A was associated with improved survival in gastric cancer sub-
jects, in contrast to its prognostic implication in CD. As the T300A
genotype is also prevalent in non-IBD subjects [30], our data suggests
a possible evolutionary benefit in the setting of non-IBD. Further-
more, genotyping of genes that are not involved in oncogenic or
tumor suppressor pathways may provide insight in stratifying sub-
jects.
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